STRADA

Summary

STRADA (STE20 related adaptor alpha, HGNC:30172) is a protein-coding gene on chromosome 17q23.3, encoding STE20-related kinase adapter protein alpha (Q7RTN6). Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1.

The protein encoded by this gene contains a STE20-like kinase domain, but lacks several residues that are critical for catalytic activity, so it is termed a ‘pseudokinase’. The protein forms a heterotrimeric complex with serine/threonine kinase 11 (STK11, also known as LKB1) and the scaffolding protein calcium binding protein 39 (CAB39, also known as MO25). The protein activates STK11 leading to the phosphorylation of both proteins and excluding STK11 from the nucleus. The protein is necessary for STK11-induced G1 cell cycle arrest. A mutation in this gene has been shown to result in polyhydramnios, megalencephaly, and symptomatic epilepsy (PMSE) syndrome. Multiple transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their full-length nature is not known.

Source: NCBI Gene 92335 — RefSeq curated summary.

At a glance

• Gene–disease (curated): polyhydramnios, megalencephaly, and symptomatic epilepsy (Definitive, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 416 total — 16 pathogenic, 5 likely-pathogenic (top 8% of genes corpus-wide)
• GTEx eGene: eQTL in 28 tissues, sQTL in 33 (q < 0.05)
• Phenotypes (HPO): 50
• ChEMBL bioactivity: 5 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.01 (LoF-tolerant), LOEUF 0.65 (unconstrained)
• MANE Select transcript: NM_001003787

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30172
Approved symbol	STRADA
Name	STE20 related adaptor alpha
Location	17q23.3
Locus type	gene with protein product
Status	Approved
Aliases	STLK5, NY-BR-96, LYK5, Stlk, STRAD
Ensembl gene	ENSG00000266173
Ensembl biotype	protein_coding
OMIM	608626
Entrez	92335

Gene structure

Transcript identifiers

Ensembl transcripts: 73 — 49 protein_coding, 11 nonsense_mediated_decay, 8 retained_intron, 5 protein_coding_CDS_not_defined

MANE Select: ENST00000336174

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 2: 8, TSL 3: 5, TSL 4: 2, TSL 5: 34

ENST00000336174, ENST00000245865, ENST00000375840, ENST00000392950, ENST00000447001, ENST00000577375, ENST00000578008, ENST00000578507, ENST00000578801, ENST00000579318, ENST00000579340, ENST00000579350, ENST00000579549, ENST00000580039, ENST00000580288, ENST00000580338, ENST00000581243, ENST00000581505, ENST00000582026, ENST00000582030, ENST00000582137, ENST00000583085, ENST00000584110, ENST00000617949, ENST00000638193, ENST00000638276, ENST00000638309, ENST00000638578, ENST00000638698, ENST00000638702, ENST00000638708, ENST00000638718, ENST00000638888, ENST00000639135, ENST00000639164, ENST00000639192, ENST00000639521, ENST00000639603, ENST00000639778, ENST00000639816, ENST00000639835, ENST00000639940, ENST00000640086, ENST00000640174, ENST00000640183, ENST00000640397, ENST00000640679, ENST00000640707, ENST00000640741, ENST00000640827, ENST00000640870, ENST00000640924, ENST00000640979, ENST00000640999, ENST00000858962, ENST00000858963, ENST00000858964, ENST00000858965, ENST00000858966, ENST00000938501, ENST00000938502, ENST00000956276, ENST00001044025, ENST00001044026, ENST00001044027, ENST00001059590, ENST00001059591, ENST00001059592, ENST00001059593, ENST00001059594, ENST00001059595, ENST00001126886, ENST00001139137

RefSeq mRNA: 15 — MANE Select: NM_001003787 NM_001003786, NM_001003787, NM_001003788, NM_001165969, NM_001165970, NM_001363786, NM_001363787, NM_001363788, NM_001363789, NM_001363790, NM_001363791, NM_001411083, NM_001411084, NM_001411085, NM_153335

CCDS: CCDS11642, CCDS32703, CCDS42367, CCDS54156, CCDS58585, CCDS86625, CCDS86626, CCDS86630, CCDS86632, CCDS86633, CCDS92377, CCDS92378, CCDS92380

Canonical transcript exons

ENST00000336174 — 13 exons

Exon	Start	End
ENSE00003509662	63704341	63704582
ENSE00003540430	63713406	63713527
ENSE00003563897	63706635	63706739
ENSE00003579321	63714006	63714108
ENSE00003611414	63707247	63707418
ENSE00003611471	63728334	63728413
ENSE00003627172	63723298	63723326
ENSE00003644002	63704005	63704047
ENSE00003649404	63710728	63710836
ENSE00003651077	63710491	63710614
ENSE00003689688	63726638	63726695
ENSE00003802073	63741741	63741799
ENSE00003847734	63702832	63703751

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 97.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.5235 / max 186.5970, expressed in 1817 samples.

Highest expression (Bgee): uterine tube, mucosa of stomach, testis, cortical plate, nerve.

Genetic regulation across tissues (GTEx eQTL / sQTL)

STRADA is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 28 tissues and its splicing (sQTL) in 33 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 61 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	3.5e-19	-0.31	17:63797521:AT:A
Nerve Tibial	eqtl	7.4e-13	-0.19	17:63711499:C:T
Cells Cultured fibroblasts	sqtl	2.7e-11	+0.52	17:63685848:A:G
Esophagus Muscularis	sqtl	2.9e-11	+0.63	17:63757269:G:T
Adipose Subcutaneous	eqtl	9.1e-11	-0.21	17:63885518:C:T
Colon Sigmoid	sqtl	5.6e-09	+0.64	17:63707888:G:A
Adrenal Gland	eqtl	2.5e-08	-0.28	17:63728941:CATT:C
Esophagus Muscularis	eqtl	3.4e-08	-0.16	17:63749477:G:A
Adipose Visceral Omentum	eqtl	5.4e-08	-0.20	17:63817218:T:C
Esophagus Mucosa	sqtl	6.3e-08	+0.48	17:63696844:C:CT
Artery Tibial	sqtl	1.4e-07	+0.49	17:63619677:T:C
Thyroid	sqtl	8.6e-07	+0.42	17:63599175:G:T
Nerve Tibial	sqtl	1.8e-06	+0.43	17:63677851:T:A
Whole Blood	eqtl	7.8e-06	+0.08	17:63846478:G:A
Esophagus Gastroesophageal Junction	sqtl	8.8e-06	+0.59	17:63628037:T:C
Colon Sigmoid	eqtl	1.1e-05	-0.14	17:63725765:G:A
Breast Mammary Tissue	sqtl	1.3e-05	-1.21	17:63513126:A:G
Skin Not Sun Exposed Suprapubic	sqtl	1.4e-05	+0.45	17:63568639:G:A
Esophagus Gastroesophageal Junction	eqtl	3.5e-05	-0.14	17:63728941:CATT:C
Brain Frontal Cortex BA9	eqtl	5.2e-05	-0.19	17:63797521:AT:A

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
167480	17.8269	1817
167481	0.5198	282
167479	0.1767	77

Top tissues by expression

showing 100 of 247 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	97.06	gold quality
mucosa of stomach	UBERON:0001199	95.46	gold quality
left testis	UBERON:0004533	95.20	gold quality
cortical plate	UBERON:0005343	95.04	gold quality
right testis	UBERON:0004534	95.02	gold quality
nerve	UBERON:0001021	94.96	gold quality
tibial nerve	UBERON:0001323	94.96	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.83	gold quality
right frontal lobe	UBERON:0002810	94.75	gold quality
ganglionic eminence	UBERON:0004023	94.60	gold quality
right ovary	UBERON:0002118	94.59	gold quality
cerebellar hemisphere	UBERON:0002245	94.47	gold quality
cerebellar cortex	UBERON:0002129	94.34	gold quality
metanephros cortex	UBERON:0010533	94.19	gold quality
body of uterus	UBERON:0009853	94.04	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.02	gold quality
left ovary	UBERON:0002119	94.00	gold quality
right adrenal gland cortex	UBERON:0035827	93.99	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.98	gold quality
endocervix	UBERON:0000458	93.91	gold quality
granulocyte	CL:0000094	93.88	gold quality
right adrenal gland	UBERON:0001233	93.80	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.65	gold quality
adenohypophysis	UBERON:0002196	93.45	gold quality
right lobe of thyroid gland	UBERON:0001119	93.42	gold quality
ectocervix	UBERON:0012249	93.42	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.39	gold quality
lower esophagus	UBERON:0013473	93.38	gold quality
sural nerve	UBERON:0015488	93.25	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.25	gold quality
left adrenal gland cortex	UBERON:0035825	93.22	gold quality
anterior cingulate cortex	UBERON:0009835	93.09	gold quality
left adrenal gland	UBERON:0001234	93.08	gold quality
descending thoracic aorta	UBERON:0002345	92.83	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.67	gold quality
skin of abdomen	UBERON:0001416	92.61	gold quality
right coronary artery	UBERON:0001625	92.60	gold quality
left lobe of thyroid gland	UBERON:0001120	92.56	gold quality
left uterine tube	UBERON:0001303	92.53	gold quality
skin of leg	UBERON:0001511	92.45	gold quality
right atrium auricular region	UBERON:0006631	92.43	gold quality
body of stomach	UBERON:0001161	92.41	gold quality
ascending aorta	UBERON:0001496	92.33	gold quality
thoracic aorta	UBERON:0001515	92.32	gold quality
spleen	UBERON:0002106	92.20	gold quality
left coronary artery	UBERON:0001626	92.07	gold quality
ventricular zone	UBERON:0003053	91.99	gold quality
tibial artery	UBERON:0007610	91.95	gold quality
popliteal artery	UBERON:0002250	91.94	gold quality
aorta	UBERON:0000947	91.90	gold quality
lower esophagus mucosa	UBERON:0035834	91.89	gold quality
apex of heart	UBERON:0002098	91.80	gold quality
monocyte	CL:0000576	91.76	gold quality
body of pancreas	UBERON:0001150	91.73	gold quality
leukocyte	CL:0000738	91.72	gold quality
upper lobe of left lung	UBERON:0008952	91.64	gold quality
cardiac atrium	UBERON:0002081	91.54	gold quality
bone marrow cell	CL:0002092	91.42	gold quality
smooth muscle tissue	UBERON:0001135	91.41	gold quality
hypothalamus	UBERON:0001898	91.31	gold quality
minor salivary gland	UBERON:0001830	91.27	gold quality
colonic epithelium	UBERON:0000397	91.25	gold quality
cerebellum	UBERON:0002037	91.16	gold quality
esophagus	UBERON:0001043	91.05	gold quality
nucleus accumbens	UBERON:0001882	91.04	gold quality
testis	UBERON:0000473	90.93	gold quality
transverse colon	UBERON:0001157	90.93	gold quality
adrenal cortex	UBERON:0001235	90.89	gold quality
spinal cord	UBERON:0002240	90.70	gold quality
thyroid gland	UBERON:0002046	90.68	gold quality
right lung	UBERON:0002167	90.61	gold quality
right lobe of liver	UBERON:0001114	90.58	gold quality
adrenal gland	UBERON:0002369	90.54	gold quality
putamen	UBERON:0001874	90.43	gold quality
omental fat pad	UBERON:0010414	90.34	gold quality
coronary artery	UBERON:0001621	90.32	gold quality
peritoneum	UBERON:0002358	90.25	gold quality
amygdala	UBERON:0001876	90.15	gold quality
vermiform appendix	UBERON:0001154	90.11	gold quality
stomach	UBERON:0000945	90.06	gold quality
stromal cell of endometrium	CL:0002255	90.04	gold quality
islet of Langerhans	UBERON:0000006	90.03	gold quality
gall bladder	UBERON:0002110	89.87	gold quality
prefrontal cortex	UBERON:0000451	89.78	gold quality
caudate nucleus	UBERON:0001873	89.67	gold quality
pituitary gland	UBERON:0000007	89.56	gold quality
pancreas	UBERON:0001264	89.52	gold quality
uterine cervix	UBERON:0000002	89.45	gold quality
esophagus mucosa	UBERON:0002469	89.29	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.08	gold quality
rectum	UBERON:0001052	88.93	gold quality
small intestine	UBERON:0002108	88.30	gold quality
upper lobe of lung	UBERON:0008948	88.19	gold quality
adrenal tissue	UBERON:0018303	88.08	gold quality
heart left ventricle	UBERON:0002084	87.92	gold quality
calcaneal tendon	UBERON:0003701	87.87	gold quality
lymph node	UBERON:0000029	87.82	gold quality
gastrocnemius	UBERON:0001388	87.74	gold quality
muscle of leg	UBERON:0001383	87.69	gold quality
adipose tissue of abdominal region	UBERON:0007808	87.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.90

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Testis	tissue	34.4	high
Postcentral gyrus	tissue	31.5
Hippocampus	tissue	26.8	medium
Pituitary gland	tissue	26.5
Locus coeruleus	tissue	25.6
Nucleus accumbens	tissue	25.0
Choroid plexus	tissue	23.1
Vagina	tissue	19.4	medium
Hippocampal formation	tissue	19.2
Spinal cord	tissue	19.1
Tonsil	tissue	19.1	high
Lymph node	tissue	19.0	high
Thymus	tissue	18.8
Superior colliculi	tissue	18.3
Medulla oblongata	tissue	18.2
Pons	tissue	18.0
Parathyroid gland	tissue	17.9	high
Skin 1	tissue	17.8	medium
Substantia nigra	tissue	17.7
Cerebellum	tissue	17.5	high
Thalamus	tissue	17.4
Fallopian tube	tissue	17.4	high
Bone marrow	tissue	17.3	high
Epididymis	tissue	17.2	medium
Hypothalamus	tissue	17.2
Periaqueductal gray	tissue	17.1
Cerebral cortex	tissue	17.0	medium
Somatosensory cortex	tissue	17.0
Frontal cortex	tissue	16.8
Midbrain	tissue	16.8
Corpus callosum	tissue	16.5
Basal ganglia	tissue	16.2	medium
Olfactory bulb	tissue	16.1
Occipital cortex	tissue	16.1
Smooth muscle	tissue	16.0	low
Septum	tissue	16.0
Spleen	tissue	15.6	medium
Prefrontal cortex	tissue	15.4
Ventral forebrain	tissue	15.2
Putamen	tissue	15.0
Amygdala	tissue	14.9
Retrosplenial and cingulate cortex	tissue	14.7
Ovary	tissue	14.5	not detected
Caudate putamen	tissue	14.5
Motor cortex	tissue	14.4
Insular cortex	tissue	14.2
Retrosplenial cortex	tissue	14.1
Entorhinal cortex	tissue	13.9
Temporal cortex	tissue	13.9
Heart muscle	tissue	13.5	high
Seminal vesicle	tissue	13.4	medium
Adrenal gland	tissue	13.0	high
Retina	tissue	12.9
Endometrium 1	tissue	12.5	high
Placenta	tissue	12.5	high
Gallbladder	tissue	12.5	high
Cervix	tissue	12.1	high
Lung	tissue	12.1	medium
Kidney	tissue	12.1	high
Esophagus	tissue	12.0	high

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Nucleus ambiguus (32.3), Precentral gyrus (31.6), Precentral gyrus, middle (29.8), Paracentral lobule, anterior (29.2), Perirhinal gyrus (28.8).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TAL1

miRNA regulators (miRDB)

Targeting STRADA by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 49 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-4696	99.48	67.48	1040
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-6739-3P	99.22	68.84	1843
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-4426	99.17	66.74	1949

Functional genomics

gnomAD constraint: pLI 0.00788, LOEUF 0.649, missense Z 1.92 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000336174 — one region, missense o/e 0.81.

Literature-anchored findings (GeneRIF, showing 12)

• Identification and characterization of an LKB1-specific adaptor protein and substrate, STRAD. Results imply that STRAD plays a key role in regulating the tumor suppressor activities of LKB1. (PMID:12805220)
• Several novel splice isoforms of STRADalpha that differentially affect the kinase activity, complex assembly, subcellular localization of LKB1 and the activation of the LKB1-dependent AMPK pathway were discovered. (PMID:17921699)
• identify a multifactored mechanism to control LKB1 localization, and they suggest that the STRADbeta-LKB1 complex might possess unique functions in the nucleus (PMID:18256292)
• LKB1 deacetylation is regulated by SIRT1 and that this in turn influences its intracellular localization, association with STRAD, kinase activity, and ability to activate AMPK. (PMID:18687677)
• STRADalpha.MO25alpha complexes containing LKB1 variants were equally effective at phosphorylating and activating AMPK, BRSK1, and BRSK2 (PMID:18854318)
• These data define a brush border induction pathway downstream of the Lkb1/Strad/Mo25 polarization complex, yet separate from other polarity events. (PMID:19386264)
• ATP and MO25alpha cooperate to maintain STRADalpha in an “active” closed conformation required for LKB1 activation. (PMID:19513107)
• study describes structure of the core heterotrimeric LKB1-STRADalpha-MO25alpha complex, revealing an unusual allosteric mechanism of LKB1 activation; structure also reveals how mutations in Peutz-Jeghers syndrome & sporadic cancers impair LKB1 function (PMID:19892943)
• aberrant nuclear accumulation of LKB1 caused by STRADalpha deficiency contributes to hyperactivation of mTORC1 signaling and disruption of neuronal lamination during corticogenesis (PMID:20424326)
• We identified for the first time a homozygous point mutation in STRADA causing PMSE. Additional bi-allelic mutations related to PMSE thus far have not been observed in Baylor approximately 6,000 consecutive clinical WES cases, supporting the rarity of this disorder. (PMID:27170158)
• Two further cases of polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, caused by a truncating variant in STRADA. (PMID:33247513)
• Type II Binders Targeting the ““GLR-Out”” Conformation of the Pseudokinase STRADalpha. (PMID:33440120)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	strada	ENSDARG00000037929
mus_musculus	Strada	ENSMUSG00000069631
rattus_norvegicus	Strada	ENSRNOG00000008637

Paralogs (35): MAP3K14 (ENSG00000006062), MAP4K3 (ENSG00000011566), MAP4K5 (ENSG00000012983), MAP2K3 (ENSG00000034152), SLK (ENSG00000065613), MAP4K4 (ENSG00000071054), STK10 (ENSG00000072786), PAK3 (ENSG00000077264), STRADB (ENSG00000082146), MAP3K1 (ENSG00000095015), STK4 (ENSG00000101109), PAK5 (ENSG00000101349), STK24 (ENSG00000102572), STK3 (ENSG00000104375), MAP4K1 (ENSG00000104814), MAP3K8 (ENSG00000107968), MAP2K6 (ENSG00000108984), NEK4 (ENSG00000114904), STK25 (ENSG00000115694), NRK (ENSG00000123572), PAK4 (ENSG00000130669), STK26 (ENSG00000134602), TAOK3 (ENSG00000135090), PAK6 (ENSG00000137843), MINK1 (ENSG00000141503), PAK1 (ENSG00000149269), TAOK2 (ENSG00000149930), TNIK (ENSG00000154310), TAOK1 (ENSG00000160551), MAP4K2 (ENSG00000168067), OXSR1 (ENSG00000172939), MAP3K19 (ENSG00000176601), PAK2 (ENSG00000180370), SBK2 (ENSG00000187550), STK39 (ENSG00000198648)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1919399) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 18 distinct phenotype terms.

Mouse phenotype (MP)	Records
cleft palate	1
malocclusion	1
domed cranium	1
tremors	1
decreased body size	1
decreased locomotor activity	1
abnormal suckling behavior	1
reduced female fertility	1
abnormal body wall morphology	1
hypotonia	1
long incisors	1
increased brain size	1
abnormal neuronal migration	1
protruding tongue	1
postnatal lethality, incomplete penetrance	1
preweaning lethality, complete penetrance	1
enlarged brain ventricles	1
ectopic neuron	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RBJ6	99.1%	Diamond
Macaca fascicularis	Q4R6X5	98.7%	Diamond
Bos taurus	Q5E9J9	95.4%	Diamond
Gallus gallus	Q5ZK47	86.0%	Diamond
Drosophila melanogaster	P83098	37.5%	Diamond
Caenorhabditis elegans	G5ECN5	35.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MAP3K3	protein-coding	4215
LIMD2	protein-coding	80774
FTSJ3	protein-coding	117246
CCDC47	protein-coding	57003
PSMC5	protein-coding	5705
SMARCD2	protein-coding	6603
DDX42	protein-coding	11325
TACO1	protein-coding	51204

Protein

Protein identifiers

STE20-related kinase adapter protein alpha — Q7RTN6 (reviewed: Q7RTN6)

Alternative names: STE20-related adapter protein, Serologically defined breast cancer antigen NY-BR-96

All UniProt accessions (31): Q7RTN6, A0A0G2JLH2, A0A1W2PNV1, A0A1W2PNV7, A0A1W2PP17, A0A1W2PP78, A0A1W2PPG2, A0A1W2PPI1, A0A1W2PPJ9, A0A1W2PPM8, A0A1W2PQ00, A0A1W2PQ20, A0A1W2PQE8, A0A1W2PQF1, A0A1W2PR00, A0A1W2PR44, A0A1W2PR65, A0A1W2PRI8, A0A1W2PRQ6, A0A1W2PRW9, A0A1W2PS04, J3KSA2, J3KSK5, J3QKR7, J3QKU4, J3QQS3, J3QR78, J3QRC1, J3QRH3, J3QS66, Q86YC8

UniProt curated annotations — full annotation on UniProt →

Function. Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation.

Subunit / interactions. Component of a trimeric complex composed of STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and stimulates its catalytic activity.

Subcellular location. Nucleus. Cytoplasm.

Disease relevance. A homozygous 7-kb deletion involving STRADA is a cause of a syndrome characterized by polyhydramnios, megalencephaly and symptomatic epilepsy.

Domain organisation. The protein kinase domain is predicted to be catalytically inactive.

Similarity. Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfamily.

Isoforms (6)

UniProt ID	Names	Canonical?
Q7RTN6-1	1	yes
Q7RTN6-2	2
Q7RTN6-3	3
Q7RTN6-4	4
Q7RTN6-5	5
Q7RTN6-6	6

RefSeq proteins (15): NP_001003786, NP_001003787, NP_001003788, NP_001159441, NP_001159442, NP_001350715, NP_001350716, NP_001350717, NP_001350718, NP_001350719, NP_001350720, NP_001398012, NP_001398013, NP_001398014, NP_699166 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR047173	STRAD_A/B-like	Family

Pfam: PF00069

UniProt features (64 total): helix 20, strand 8, splice variant 7, mutagenesis site 7, turn 7, sequence conflict 4, modified residue 4, sequence variant 3, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

4 structures by resolution:

PDB	Title	Method	Resolution (Å)
1UPK	Crystal structure of MO25 in complex with a C-terminal peptide of STRAD	X-RAY DIFFRACTION	1.85
3GNI	Structure of STRAD and MO25	X-RAY DIFFRACTION	2.35
2WTK	Structure of the heterotrimeric LKB1-STRADalpha-MO25alpha complex	X-RAY DIFFRACTION	2.65
8VSU	Cryo-EM structure of LKB1-STRADalpha-MO25alpha heterocomplex	ELECTRON MICROSCOPY	2.86

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7RTN6-F1	80.46	0.64

Human Protein Atlas

Protein class: Enzymes, Kinases, STE Ser/Thr protein kinases, Predicted intracellular proteins, Disease related genes, Potential drug targets, Human disease related genes, Congenital malformations, Congenital malformations of the nervous system

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; nucleoplasm

Antibody reliability (HPA): IH approved · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4)

Type	Positions
Phosphoserine	2, 46
Phosphothreonine	329, 419

Mutagenesis-validated functional residues (7)

Position	Phenotype
185	suppresses stk11/lkb1 activation without affecting complex assembly.
231	inhibits interaction with stk11/lkb1; when associated with a-.
233	inhibits interaction with stk11/lkb1; when associated with a-.
241	inhibits interaction with stk11/lkb1.
251	inhibits interaction with stk11/lkb1.
329	loss of stk11/lkb1-mediated phosphorylation.
419	loss of stk11/lkb1-mediated phosphorylation.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-380972	Energy dependent regulation of mTOR by LKB1-AMPK	curated
R-HSA-165159	MTOR signalling	—
R-HSA-162582	Signal Transduction	—

MSigDB gene sets: 240 (showing top): TGCGCANK_UNKNOWN, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_NUCLEAR_TRANSPORT, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOBP_NUCLEAR_EXPORT, GOBP_ACTIVATION_OF_PROTEIN_KINASE_ACTIVITY, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOCC_TRANSFERASE_COMPLEX_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS

GO Biological Process (4): protein export from nucleus (GO:0006611), activation of protein kinase activity (GO:0032147), G1 to G0 transition (GO:0070314), protein phosphorylation (GO:0006468)

GO Molecular Function (7): ATP binding (GO:0005524), kinase binding (GO:0019900), protein kinase activator activity (GO:0030295), protein serine/threonine kinase activator activity (GO:0043539), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), intracellular protein-containing complex (GO:0140535), serine/threonine protein kinase complex (GO:1902554), protein-containing complex (GO:0032991)

Reactome top-level categories

2 top-level categories:

Category	Pathways
MTOR signalling	1
Signal Transduction	1

GO top-level categories

29 GO namespaces:

Category	Terms
cellular anatomical structure	3
intracellular protein transport	1
nuclear export	1
positive regulation of protein kinase activity	1
cell cycle process	1
phosphorylation	1
protein modification process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
enzyme binding	1
protein kinase activity	1
kinase activator activity	1
protein kinase regulator activity	1
protein serine/threonine kinase activity	1
protein kinase activator activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
protein-containing complex	1
protein kinase complex	1
cellular_component	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 11 of 18 annotations. The rest are phylogenetic / computational / electronic (IEA).

11 experimentally-supported GO terms:

GO term	NS	Evidence
G1 to G0 transition	BP	physical interaction
activation of protein kinase activity	BP	direct assay
protein export from nucleus	BP	direct assay
cytoplasm	CC	direct assay
cytosol	CC	direct assay
intracellular protein-containing complex	CC	direct assay
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
kinase binding	MF	physical interaction
protein kinase activator activity	MF	direct assay
protein serine/threonine kinase activator activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 596 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STRADA	CAB39	Q9Y376	979
STRADA	STK11	Q15831	944
STRADA	CAB39L	Q9H9S4	845
STRADA	GOLGA2	Q08379	813
STRADA	RELN	P78509	717
STRADA	GOLPH3	Q9H4A6	691
STRADA	STK11IP	Q8N1F8	623
STRADA	GORASP1	Q9BQQ3	614
STRADA	TSC2	P49815	601
STRADA	MTOR	P42345	587
STRADA	LRP8	Q14114	564
STRADA	USO1	O60763	552
STRADA	YWHAQ	P27348	526
STRADA	VLDLR	P98155	516
STRADA	NPRL3	Q12980	496

IntAct

Human interaction partners of STRADA in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
STK11	physical association	0.960	12
CAB39	physical association	0.560	3
BIRC6	physical association	0.400	1
CFTR	physical association	0.370	1

BioGRID (61 interactions; top human partners by supporting records): STK11 (Affinity Capture-MS; 20 records), CAB39 (Co-crystal Structure; 4 records), CAB39L (Affinity Capture-MS; 3 records), C5orf24 (Affinity Capture-MS; 2 records), LBHD1 (Affinity Capture-MS; 2 records), PIP4K2A (Affinity Capture-MS; 2 records), XPO1 (Affinity Capture-MS; 2 records), AHSG (Affinity Capture-MS), AMY1A (Affinity Capture-MS), BIRC6 (Affinity Capture-MS), CCT3 (Affinity Capture-MS), CFTR (PCA), CLASP2 (Affinity Capture-MS), DCAF10 (Proximity Label-MS), DDX58 (Affinity Capture-RNA)

SIGNOR signaling

showing 3 of 4 signaling interactions:

A	Effect	B	Mechanism
STRADA	“up-regulates activity”	STK11	binding
STK11	“up-regulates activity”	STRADA	phosphorylation
STRADA	“up-regulates quantity”	STK11	phosphorylation

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
LKB1-STRAD-MO25 complex	3	CAB39, STK11, STRADA

Disease & clinical

Genetic variants

Variant evidence for STRADA: 416 ClinVar records (21 pathogenic / likely pathogenic); 2 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

416 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	16
Likely pathogenic	5
Uncertain significance	187
Likely benign	184
Benign	2

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 21 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
842228	NM_001003787.4(STRADA):c.682C>T (p.Arg228Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	2
663375	NM_001003787.4(STRADA):c.37-1G>C	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
1068097	NM_001003787.4(STRADA):c.36+1G>A	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
536756	NM_001003787.4(STRADA):c.1036C>T (p.Arg346Ter)	Pathogenic	criteria provided, single submitter	1
856509	NM_001003787.4(STRADA):c.254_255del (p.Val85fs)	Pathogenic	criteria provided, single submitter	1
952543	NM_001003787.4(STRADA):c.28C>T (p.Arg10Ter)	Pathogenic	criteria provided, single submitter	1
2074680	NM_001003787.4(STRADA):c.207C>G (p.Tyr69Ter)	Pathogenic	criteria provided, single submitter	1
2700850	NM_001003787.4(STRADA):c.101del (p.Pro34fs)	Pathogenic	criteria provided, single submitter	1
2704723	NM_001003787.4(STRADA):c.156del (p.Phe53fs)	Pathogenic	criteria provided, single submitter	1
2749405	NM_001003787.4(STRADA):c.630C>G (p.Tyr210Ter)	Pathogenic	criteria provided, single submitter	1
2790856	NM_001003787.4(STRADA):c.751C>T (p.Gln251Ter)	Pathogenic	criteria provided, single submitter	1
3644079	NM_001003787.4(STRADA):c.828_853del (p.Val277fs)	Pathogenic	criteria provided, single submitter	1
3649917	NM_001003787.4(STRADA):c.54del (p.Lys18fs)	Pathogenic	criteria provided, single submitter	1
4282368	NM_001003787.4(STRADA):c.891dup (p.Cys298fs)	Pathogenic	criteria provided, single submitter	1
3689518	NM_001003787.4(STRADA):c.457+1G>T	Likely pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore STRADA’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 37 predictions of 935):

Position(s)	Effect	Δscore	Sites
17:63706633–63706634	donor_loss	1.0000	4
17:63706740–63706741	acceptor_loss	1.0000	5
17:63706746–63706747	acceptor_gain	1.0000	2
17:63710489–63710490	donor_loss	1.0000	5
17:63710502	donor_gain	1.0000
17:63710615–63710616	acceptor_loss	1.0000	5
17:63710726	donor_loss	1.0000
17:63710837–63710838	acceptor_loss	1.0000	5
17:63713404–63713405	donor_loss	1.0000	3
17:63713528–63713529	acceptor_loss	1.0000	6

AlphaMissense

1,162 missense substitutions predicted likely pathogenic (of 2,840 scored), across 276 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M287	9	0.937	0.997
M282	9	0.855	0.975
D261	8	0.999	1.000
D301	8	0.995	0.999
H193	8	0.991	0.998
H187	8	0.986	0.997
F279	8	0.982	1.000
S245	8	0.980	1.000
H200	8	0.974	0.997
S264	8	0.961	1.000
F233	8	0.937	0.996
H353	8	0.930	0.991
H127	8	0.929	0.992
N274	8	0.929	0.998
F352	8	0.929	0.996
F378	8	0.927	0.995
F348	8	0.920	0.996
F137	8	0.915	0.994
F125	8	0.895	0.987
D157	8	0.873	0.940

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	unfavorable	3.03e-05
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	0.000426

Disease associations

OMIM: gene MIM:608626 | disease phenotypes: MIM:611087, MIM:117100

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
polyhydramnios, megalencephaly, and symptomatic epilepsy	Definitive	Autosomal recessive	5

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (11 panels, 11 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

11 panels:

Panel	Rating
DDG2P	green
Early onset or syndromic epilepsy	green
Fetal anomalies	green
Hydrocephalus	green
Hypotonic infant	green
Intellectual disability	green
Leukodystrophy, childhood onset	green
Nephrocalcinosis or nephrolithiasis	green
Paediatric disorders	green
Unexplained death in infancy and sudden unexplained death in childhood	green
Unexplained young onset end-stage renal disease	green

Mondo (2): polyhydramnios, megalencephaly, and symptomatic epilepsy (MONDO:0012611), self-limited epilepsy with centrotemporal spikes (MONDO:0007295)

Orphanet (2): Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome (Orphanet:500533), Self-limited epilepsy with centrotemporal spikes (Orphanet:1945)

HPO phenotypes

50 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000121	Nephrocalcinosis
HP:0000154	Wide mouth
HP:0000179	Thick lower lip vermilion
HP:0000194	Open mouth
HP:0000215	Thick upper lip vermilion
HP:0000256	Macrocephaly
HP:0000275	Narrow face
HP:0000276	Long face
HP:0000297	Facial hypotonia
HP:0000316	Hypertelorism
HP:0000348	High forehead
HP:0000431	Wide nasal bridge
HP:0000486	Strabismus
HP:0000873	Diabetes insipidus
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001288	Gait disturbance
HP:0001290	Generalized hypotonia
HP:0001344	Absent speech
HP:0001355	Megalencephaly
HP:0001382	Joint hypermobility
HP:0001508	Failure to thrive
HP:0001533	Slender build
HP:0001561	Polyhydramnios
HP:0001622	Premature birth
HP:0001631	Atrial septal defect
HP:0001635	Congestive heart failure
HP:0001999	Abnormal facial shape
HP:0002003	Large forehead
HP:0002119	Ventriculomegaly
HP:0002133	Status epilepticus
HP:0002307	Drooling
HP:0002384	Focal impaired awareness seizure
HP:0002446	Astrocytosis
HP:0002540	Inability to walk
HP:0002553	Highly arched eyebrow
HP:0003199	Decreased muscle mass
HP:0006829	Severe muscular hypotonia
HP:0010804	Tented upper lip vermilion
HP:0011182	Interictal epileptiform activity
HP:0011344	Severe global developmental delay
HP:0011968	Feeding difficulties
HP:0012371	Hyperplasia of midface
HP:0012430	Cerebral white matter hypoplasia
HP:0012469	Infantile spasms
HP:0030680	Abnormal cardiovascular system morphology
HP:0030891	Periventricular white matter hyperintensities

GWAS associations

2 associations:

Study	Trait	p-value
GCST90002403_80	Red blood cell count	2e-12
GCST000175_10	Height	7e-7

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0004305	erythrocyte count

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
C567020	Polyhydramnios, Megalencephaly, And Symptomatic Epilepsy *(supp.)*

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL1795198 (SINGLE PROTEIN), CHEMBL3885534 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 18,430 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

5 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1789941	RUXOLITINIB	4	12,161
CHEMBL377300	BRIVANIB	3	1,784
CHEMBL1231124	AZD-1480	2	1,632
CHEMBL1088751	PH-797804	2	726
CHEMBL296468	BMS-387032	1	2,127

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — STLK subfamily

ChEMBL bioactivities

10 potent at pChembl≥5 of 10 total, top 10 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.70	Kd	19.76	nM	CHEMBL3752910
7.70	ED50	19.76	nM	CHEMBL3752910
6.50	Kd	316	nM	AZD-1480
6.17	Kd	672	nM	PH-797804
6.00	IC50	1000	nM	TP-030-1
6.00	IC50	1000	nM	TP-030-2
6.00	IC50	1000	nM	TP-030n
5.94	Kd	1137	nM	BRIVANIB
5.55	Kd	2807	nM	BMS-387032
5.43	Kd	3672	nM	RUXOLITINIB

PubChem BioAssay actives

6 with measured affinity, of 287 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149947: Binding affinity to human STRADA incubated for 45 mins by Kinobead based pull down assay	kd	0.0198	uM
5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	1425186: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.3160	uM
3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1-pyridinyl]-N,4-dimethylbenzamide	1425186: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.6720	uM
(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol	1425186: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.1370	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	1425186: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	2.8070	uM
Ruxolitinib	1425186: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	3.6720	uM

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
methacrylaldehyde	affects cotreatment, increases expression, increases oxidation, increases abundance	2
Acrolein	affects cotreatment, increases expression, increases oxidation, increases abundance	2
Cisplatin	increases expression, decreases response to substance, affects cotreatment	2
Ozone	affects cotreatment, increases expression, increases oxidation, increases abundance	2
GSK-J4	decreases expression	1
alpha-pinene	affects cotreatment, increases expression, increases oxidation, increases abundance	1
beta-lapachone	increases expression	1
afimoxifene	decreases expression, decreases reaction	1
butyraldehyde	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases expression, increases oxidation	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Cannabidiol	decreases expression	1
Coumestrol	increases expression	1
Estrogens	decreases expression, decreases reaction	1
Ethyl Methanesulfonate	increases expression	1
Methotrexate	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Gold Compounds	increases expression	1

ChEMBL screening assays

47 unique, capped per target: 47 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1838322	Binding	Inhibition of human STLK5 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β. — *Bioorg Med Chem Lett*

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TQ98	HAP1 STRADA (-) 1	Cancer cell line	Male
CVCL_TQ99	HAP1 STRADA (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00004637	Phase 4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	Phase 4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	Phase 4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	Phase 4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	Phase 4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	Phase 4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	Phase 4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	Phase 4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	Phase 4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	Phase 4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	Phase 4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	Phase 4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	Phase 4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	Phase 4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	Phase 4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	Phase 4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	Phase 4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	Phase 4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	Phase 4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	Phase 4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	Phase 4	COMPLETED	RNS® System LTT Study
NCT00610532	Phase 4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	Phase 4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	Phase 4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	Phase 4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	Phase 4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	Phase 4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	Phase 4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	Phase 4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	Phase 4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	Phase 4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	Phase 4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	Phase 4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	Phase 4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	Phase 4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	Phase 4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	Phase 4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	Phase 4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	Phase 4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	Phase 4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy
NCT01309074	Phase 4	WITHDRAWN	Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline
NCT01318408	Phase 4	COMPLETED	Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
NCT01498822	Phase 4	COMPLETED	Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
NCT01546688	Phase 4	TERMINATED	A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
NCT01607346	Phase 4	TERMINATED	An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
NCT01627860	Phase 4	COMPLETED	First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients
NCT01689649	Phase 4	COMPLETED	A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy
NCT01713777	Phase 4	COMPLETED	Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design
NCT01733394	Phase 4	COMPLETED	Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)
NCT01804322	Phase 4	COMPLETED	Standardized Educational Plan for Epilepsy Patients With Comorbidities
NCT01932502	Phase 4	UNKNOWN	Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy
NCT01995825	Phase 4	COMPLETED	Lamotrigine Bioequivalence
NCT02100644	Phase 4	COMPLETED	Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study
NCT02178995	Phase 4	COMPLETED	Methylphenidate Treatment of Attention Deficits in Epilepsy
NCT02205931	Phase 4	UNKNOWN	Ketogenic Diet in Infants With Epilepsy (KIWE)
NCT02362373	Phase 4	COMPLETED	Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
NCT02404168	Phase 4	COMPLETED	BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients
NCT02429596	Phase 4	UNKNOWN	A Trial of Generic Substitution of Antiepileptic Drugs
NCT02633241	Phase 4	COMPLETED	A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
NCT02645279	Phase 4	UNKNOWN	Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for STRADA across ~30M SureChEMBL compounds — explore on Sugi Predict.